Limits...
MicroRNA therapeutics in cardiovascular medicine.

Thum T - EMBO Mol Med (2011)

Bottom Line: Cardiovascular diseases are the most common causes of human morbidity and mortality despite significant therapeutic improvements by surgical, interventional and pharmacological approaches in the last decade.MicroRNAs (miRNAs) are important and powerful mediators in a wide range of diseases and thus emerged as interesting new drug targets.An array of animal and even human miRNA-based therapeutic studies has been performed, which validate miRNAs as being successfully targetable to treat a wide range of diseases.

View Article: PubMed Central - PubMed

Affiliation: Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany. thum.thomas@mh-hannover.de

Show MeSH

Related in: MedlinePlus

Identified miRNAs to be of therapeutic interest during cardiovascular disease.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3376835&req=5

fig01: Identified miRNAs to be of therapeutic interest during cardiovascular disease.

Mentions: This highlights the need for further understanding of underlying mechanisms and development of innovative effective therapies for heart diseases. A variety of cardiovascular diseases, such as coronary artery disease, hypertension, myocardial infarction, valvular heart diseases, myocarditis and genetic forms of cardiomyopathies often result in a phenotypically similar endpoint, which is heart failure (Hill & Olson, 2008). Exposure of the heart to different stressors leads to cardiac remodelling with finally detrimental outcomes (Fig 1). At the cellular level, there is fibroblast activation and proliferation with subsequently increased growth factor secretion and extracellular matrix (ECM) production leading to fibrosis and further decline in cardiac function (Hill & Olson, 2008). Impaired vascularization and low capillary density as well as inflammatory processes further contribute to the development of heart failure (Fiedler et al, 2011; Heymans et al, 2009). Indeed, alterations of non-cardiomyocytes such as cardiac fibroblasts and endothelial cells strongly impact on cardiomyocyte and thus on general cardiac function.


MicroRNA therapeutics in cardiovascular medicine.

Thum T - EMBO Mol Med (2011)

Identified miRNAs to be of therapeutic interest during cardiovascular disease.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3376835&req=5

fig01: Identified miRNAs to be of therapeutic interest during cardiovascular disease.
Mentions: This highlights the need for further understanding of underlying mechanisms and development of innovative effective therapies for heart diseases. A variety of cardiovascular diseases, such as coronary artery disease, hypertension, myocardial infarction, valvular heart diseases, myocarditis and genetic forms of cardiomyopathies often result in a phenotypically similar endpoint, which is heart failure (Hill & Olson, 2008). Exposure of the heart to different stressors leads to cardiac remodelling with finally detrimental outcomes (Fig 1). At the cellular level, there is fibroblast activation and proliferation with subsequently increased growth factor secretion and extracellular matrix (ECM) production leading to fibrosis and further decline in cardiac function (Hill & Olson, 2008). Impaired vascularization and low capillary density as well as inflammatory processes further contribute to the development of heart failure (Fiedler et al, 2011; Heymans et al, 2009). Indeed, alterations of non-cardiomyocytes such as cardiac fibroblasts and endothelial cells strongly impact on cardiomyocyte and thus on general cardiac function.

Bottom Line: Cardiovascular diseases are the most common causes of human morbidity and mortality despite significant therapeutic improvements by surgical, interventional and pharmacological approaches in the last decade.MicroRNAs (miRNAs) are important and powerful mediators in a wide range of diseases and thus emerged as interesting new drug targets.An array of animal and even human miRNA-based therapeutic studies has been performed, which validate miRNAs as being successfully targetable to treat a wide range of diseases.

View Article: PubMed Central - PubMed

Affiliation: Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany. thum.thomas@mh-hannover.de

Show MeSH
Related in: MedlinePlus